No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated. Methods In four separate clinical pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen ® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated. Results Areas under the concentration-time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin, where it was reduced by 21%. Maximum concentrations (C max ) were generally lower following coadministration with dulaglutide, with statistically significant reductions (90% confidence intervals of geometric least squares means ratios outside 0.80-1.25) for all analytes except R-warfarin. For all analytes, there was a general trend for the time to C max (t max ) to increase following coadministration with dulaglutide. For warfarin, dulaglutide coadministration had no statistically significant effect on the maximum INR (INR max ); however, a 2% increase in area under the INR curve (AUC INR ) was observed. Con…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with dulaglutide showed similar inhibitory effects on Cmax and tmax, but the AUC of atorvastatin was reduced (0.786, 90% CI 0.752–0.821) [15], as with co-administration of albiglutide [29].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [15]
In the citing paper
“All other GLP1 agonists resulted in a lower Cmax and a delayed tmax, but the AUC remained unaffected [15, 22, 32, 36].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [15]
In the citing paper
“Exceptions were a 19 % and a 22 % reduction in warfarin Cmax when administered with lixisenatide or dulaglutide (both doses of 1.5 mg and 4.5 mg), respectively [15, 31, 32] that were not considered to be of clinical importance.”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [15]
In the citing paper
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [15]
Citations
Cites
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Given the delay in GE associated with GLP-1 RAs, albeit more predominant in short-acting compounds [17], there was interest in evaluating the effects of dulaglutide on the pharmacokinetics (PK) of selected orally administered drugs.”
BackgroundHuman P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN*
O'Reilly, R. A., Aggeler, P. M., & Leong, L. S. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104839 · Cited by 209
Jones, K. L., Horowitz, M., Wishart, M. J., Af, M., Harding, P., & Chatterton, B. E. (1995) · PubMed · Cited by 164
Näslund, E., King, N., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M. (2004) · British Journal of Nutrition · doi:10.1079/bjn20031064 · Cited by 160
Cited by
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 188
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
Skelley, J. W., Swearengin, K., York, A. L., & Glover, L. H. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.037 · Cited by 66
Yang, Y., Li, P., Zhang, Z., Wang, Z., Liu, L., & Liu, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197023 · Cited by 37
Metadata
- Authors
- de la Peña, A., Cui, X., Geiser, J., & Loghin, C.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- Clinical Pharmacokinetics
- Published
- 2017-03-29
- Volume
- 56
- Issue
- 11
- Pages
- 1415-1427
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2603750270
- Cited by
- 31
- References
- 28
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- dulaglutide, digoxin, warfarin, atorvastatin, oral contraceptives, drug-drug interactions, pharmacokinetics, pharmacodynamics, gastric emptying, GLP-1 receptor agonists, type 2 diabetes, dose adjustment, international normalized ratio
- MeSH terms
- Atorvastatin, Administration, Oral, Adolescent, Adult, Aged, Contraceptives, Oral, Digoxin, Drug Interactions, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Injections, Subcutaneous, Male, Middle Aged, Recombinant Fusion Proteins, Warfarin, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. https://app.cochat.ai/papers/10.1007/s40262-017-0531-7
- The paper
- de la Peña, A., Cui, X., Geiser, J., & Loghin, C. (2017). No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-017-0531-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.